Pharmaceuticals, Biotechnology and Life Sciences
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses…
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close…
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering…
CHATHAM, N.J., June 13, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated…
– Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models –…
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial…
— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator…
Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results //…
Mr. Webster brings more than 20 years of executive level experience in the life sciences industryGARDEN CITY, N.Y., June 13,…